Loading clinical trials...
Loading clinical trials...
Phase 1/2a Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab
Conditions
Interventions
BI-1206
Rituximab
+1 more
Locations
27
United States
Emory University Hospital
Atlanta, Georgia, United States
Norton Cancer Institute - St. Matthews 3991 Dutchmans Lane Medical Plaza II, Suite 405
Louisville, Kentucky, United States
Hospital São Rafael
Salvador, Estado de Bahia, Brazil
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer
Curitiba, Brazil
Ruschel Medicina e Pesquisa Clínica
Rio de Janeiro, Brazil
Start Date
May 16, 2018
Primary Completion Date
September 30, 2026
Completion Date
September 30, 2026
Last Updated
April 24, 2025
NCT05755087
NCT07098364
NCT05672251
NCT06461182
NCT05025800
NCT03625037
Lead Sponsor
BioInvent International AB
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions